CONSORT diagram of the study. A total of 48 patients received study treatment, consisting at least of 1 dose of R, bendamustine, and ibrutinib. Thirty-nine patients completed 1 or more cycles of R, bendamustine, and ibrutinib, and 9 patients were removed from the study prior to completion of cycle 1 for rapid disease progression or adverse events.